"name","id","instanceType","label","rationale","description","uuid:ID"
"Study Design 1","StudyDesign_1","StudyDesign","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","ea270f7b-6d44-4973-b070-dc33818aa776"
